I
MRKR icon

INVST’s Marker Therapeutics MRKR Stock Holding History

INVST’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.7K Buy
29,000
+2,000
+7% +$3.17K ﹤0.01% 332
2025
Q4 		$40.2K Sell
27,000
-2,000
-7% -$2.27K ﹤0.01% 305
2025
Q3 		$25.9K Buy
29,000
+5,600
+24% +$6.91K ﹤0.01% 307
2025
Q2 		$35.8K Hold
23,400
– – ﹤0.01% 296
2025
Q1 		$28.8K Buy
23,400
+3,163
+16% +$5.79K ﹤0.01% 269
2024
Q4 		$62.9K Buy
20,237
+237
+1% +$839 0.01% 244
2024
Q3 		$56.4K Buy
+20,000
New +$79.1K 0.01% 248

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

INVST's MRKR Position: Q1 2026 in Review

INVST increased its Marker Therapeutics (MRKR) stake by 7.4% in Q1 2026, buying an estimated $3.17K and bringing the position to 29,000 shares worth $37.7K. The position accounts for ﹤0.01% of the portfolio, ranked #332.

INVST first reported a position in MRKR in Q3 2024 and has held it in 7 quarters since. The position peaked at $62.9K in Q4 2024. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • INVST held 29,000 shares of Marker Therapeutics worth $37.7K as of Q1 2026.
  • INVST bought 2,000 Marker Therapeutics shares in Q1 2026, an estimated $3.17K.
  • Marker Therapeutics made up ﹤0.01% of INVST's portfolio in Q1 2026, its #332 holding.
  • INVST first reported a position in Marker Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • INVST's Marker Therapeutics position peaked at $62.9K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on INVST's 13F filing for Q1 2026, filed 13 May 2026.